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ABSTRACT
Objective: The objective of the study was to determine health-related quality of life (HRQOL) in patients with chronic obstructive pulmonary disease 
(COPD) and to measure differences in HRQOL according to gender and severity of COPD.
Methods: An observational study was conducted over a period of 9 months. A total of 100 COPD patient’s data were collected regarding patients age, 
gender, smoking status, and clinical characteristics using an SF-12 health survey questionnaire.
Results: The total study population of 100 patients, 78% were men and 22% of women with a mean age of 65.4±13.2 years. The spirometry 
measurements, the mean forced expiratory volume 1 (FEV1) value was 57.2±10.4. HRQOL correlated significantly with FEV1 values (p=0.9760, 
p<0.0001). The severity of the disease was mild in 22%, moderate in 41%, severe in 24%, and very severe in 13% of patients. HRQOL was compared 
between men and women; the mean mental component summary scores were significantly higher in women (65.6±10.7) than in men (59.2±11.6). An 
inverse significant correlation between HRQOL and degree of dyspnea was observed (p=−0.9218, p<0.0001).
Conclusion: The mental health status is essentially higher in women when contrasted with men. HRQOL is impaired, and moreover, it progressively 
worsens with increasing severity of the disease. This study shows that patients with higher smoking index are having more likelihood of developing 
the COPD disease and dyspnea has a great impact on HRQOL of patients. Evaluation of COPD patients should not be based only on pulmonary function 
tests but also by considering and estimating the patient’s HRQOL.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a progressive and 
partially reversible obstruction of air flow related with lungs abnormal 
inflammatory response to gasses and different poisonous particles [1].
Over 3 million people died because of COPD in 2005 relating to 5% of 
all deaths globally and it is estimated to be the third leading cause of 
death by 2030. According to the World Health Organization estimates, 
65  million people have moderate to severe COPD [2]. India contributes 
a noteworthy and developing rate of COPD mortality, which is assessed 
to be among the most elevated on the planet; i.e., more than 64.7 
evaluated age institutionalized passing rate per 100,000 among both 
guys and females. This would mean around 556,000 in the event of 
India, which is over 20% out of a world aggregate of 2,748,000 every 
year [3].
The most common manifestations of COPD are breathlessness, or a 
“requirement for air,” excessive secretion of sputum, and cough. The 
objectives of COPD treatment are to prevent disease progression, 
enhance exercise tolerance, relieve symptoms, boost health status, 
prevent and manage exacerbations, prevention, and management of 
complications, and reduce the rate of mortality. COPD primary risk 
factors include tobacco smoking, indoor air contamination (such as 
biomass fuel utilized for cooking and warming), occupational dust 
and chemicals (vapors, irritants, and fumes), outdoor air pollution [4]. 
A basic test called spirometry can be utilized to diagnose COPD, which 
measures how profoundly a person can breathe and how fast air can 
move in and out of the lungs. Spirometry is required to make the analysis, 
the presence of a post-bronchodilator forced expiratory volume 1 
(FEV1)/forced vital capacity <0.70 affirms the presence of persistent 
airflow limitation and thus of COPD in patients with appropriate 
symptoms and significant exposures to harmful stimuli, spirometry is 
the most reproducible and target measurement of airflow limitation in 
patients. It is a noninvasive and promptly accessible test [5].
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines have identified the objectives of treatment for COPD 
patients, these include the patients’ goals of improved emotional 
function (health-related quality of life [HRQOL]), exercise tolerance 
and critical clinical objectives, for example, prevent disease progression 
and minimization of symptoms [6]. Measures of HRQOL, along with 
estimations of morbidity and mortality rate, can also be used for 
making medical decisions regarding treatment because they include 
information on abilities, impairments, symptoms, and psychological 
effects of the disease [7].
The Short Form Health Survey (SF-12) scale scores are estimated 
for four of the health concepts (physical functioning, role-physical, 
role-emotional, and mental health) using two items each, whereas 
the remaining four (general health, bodily pain, vitality, and social 
functioning) are spoken by a single item [8].
This study mostly focuses on the HRQOL in COPD patients and to 
measure the difference of HRQOL based on COPD severity.
METHODS
Study design
A prospective observational study was conducted in the Department 
of General Medicine, in the Tertiary Care Hospital, Chennai, India. The 
study was conducted over a period of 9 months. A total of 100 COPD 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i8.19199
Research Article
245
Asian J Pharm Clin Res, Vol 10, Issue 8, 2017, 244-247
 Varughese and Jayakumari 
patient’s data were collected regarding patients age, gender, smoking 
status, and clinical characteristics. The study protocol was approved by 
the Institutional Ethics Committee.
Patients
Patients of both sexes, aged 18 years above, with a previous diagnosis 
of COPD (confirmed by medical history and spirometry) and patient 
willing to participate and complete the simple SF-12 questionnaire 
were eligible for the study. The diagnosis of the disease was performed 
according to the criteria of the GOLD based on the demonstration 
through a forced spirometry, post-bronchodilator FEV1. Spirometry 
ought to be performed after the organization of a sufficient measurement 
of no <1 short-acting inhaled bronchodilator keeping in mind the end 
goal to limit inconstancy. The COPD seriousness was evaluated by the 
constrained expiratory volume (FEV1) in one moment: That is gentle 
(FEV1≥80% anticipated), direct (50%≤FEV1<80% anticipated), 
extreme (30%≤FEV1<50% anticipated), and exceptionally extreme 
(FEV1<30% anticipated). The COPD severity was graded based on 
the FEV1 in 1 second: That is mild (FEV1 more than or equal to 80% 
predicted), moderate (FEV1≤50% or even <80% predicted), severe 
(FEV1 less than or equal or even less than 50% predicted), and very 
severe (FEV1<30% predicted). Pregnancy and lactating woman and 
those patients suffering from any physical and/or psychiatric disease 
were also excluded from this study. The patients with more than 80% 
of missing data in their medical records were also excluded from the 
study.
Data collection
Interviews were carried out during the ward rounds. All data were 
collected using a Short Form 12 Health Survey Questionnaire (SF-12), 
in which the following variables were recorded: Age; gender; smoking 
habit (current smoker, never smoker, and ex-smoker); year of COPD 
diagnosis; data’s of the last spirometry measurement (FEV1 values).
Patients were administered with the Short Form 12 Health Survey 
Questionnaire (SF-12), which contains 12 items. These 12 items explain 
more than 90% of the variance of the physical and mental component 
scales. From them two scores can be calculated, the physical (physical 
component summary-12 [PCS-12]) and the mental (mental component 
summary-12 [MCS-12]) component summary. The SF-12 scores run 
from 0 to 100, where higher scores indicate better HRQOL. A score 
more than 60 has been regarded as high HRQOL, 40-60 as normal 
HRQOL, and <40 as impaired (low) HRQOL. A standard Tamil version of 
the SF-12 questionnaire has been provided.
The Medical Research Council (MRC) dyspnea scale was employed to 
analyze the degree of breathlessness by relating to activity in this study 
population.
Statistical analysis
The GraphPad Prism 5.01 was used for the analysis of data. Continuous 
variables are expressed as the mean and standard deviation (SD), 
whereas the qualitative variables are described as percentages. 
Differences of HRQOL of patients based on the severity of COPD 
were analyzed with the paired Student’s t-test and the confidence 
intervals were calculated at the 95% level. The Spearman’s rank-order 
correlation coefficient (ρ) was calculated to assess the relationship 
between HRQOL, FEV1, and Dyspnea. Statistical significance was set at 
p≤0.05.
RESULTS
The total study population of 100 patients, 78% were men and 22% of 
women; with a mean (±SD) age of 65.4±13.2 years. This study shows 
that 48% were ex-smokers and 22% were current smokers and 30% 
were never smokers. Patients demographic is shown in Table 1.
With regard to the last spirometry measurements, the mean FEV1 value 
was 57.2±10.4. The severity of COPD disease was mild in 22% of cases, 
moderate in 41%, severe in 24%, and very severe in 13% as shown in 
Table 2. There were differences in COPD severity according to gender, 
with significantly higher percentages of men compared to women.
Most of the patients (63%) had a moderate degree of dyspnea (MRC 
dyspnea scale: Grade 2). However, 16% of men showed a moderately 
severe degree of dyspnea (MRC dyspnea scale: Grades 4 and 5) 
compared with 21% of women.
The mean PCS-12 and MCS-12 scores were 40.7±9.4 and 64.3±12.1, 
respectively. General health and physical functioning domains were 
those with the lowest scores (i.e., physical health domain) as shown 
in Fig. 1, whereas role emotional and social functioning domains were 
those with the highest scores (i.e., mental health) were presented in 
Table 3.
Based on the results of the SF-12 questionnaire, HRQOL was graded as 
normal (40-60 points) by 64% of patients and lower (<40 points) by 
36% of patients. When HRQOL in men and women was compared, there 
Table 1: Patients demographic and clinical characteristics
Characteristics Number (%) Mean±SD (range)














Current smoker 22 (22)
SD: Standard deviation
Table 2: Clinical characteristics of patients







SD: Standard deviation, FEV: Forced expiratory volume, COPD: Chronic 
obstructive pulmonary disease













SD: Standard deviation, PCS-12: Physical component summary-12, 
MCS-12: Mental component summary-12, COPD: Chronic obstructive 
pulmonary disease, HRQOL: Health-related quality of life
246
Asian J Pharm Clin Res, Vol 10, Issue 8, 2017, 244-247
 Varughese and Jayakumari 
were no significant differences in the mean PCS-12 scores (40.4±10.1 
versus 39.3±9.7), but the mean MCS-12 scores were significantly higher 
in women (65.6±10.7) than in men (59.2±11.6).
HRQOL correlated significantly with FEV1 values (p=0.9760, p<0.0001). 
The mean scores of the PCS and the MCS in COPD patients according to 
the severity of the disease were illustrated in Fig. 2. As expected, an 
inverse significant correlation between HRQOL and degree of dyspnea 
was observed (p=−0.9218, p<0.0001).
DISCUSSION
In COPD patients, the measurement of HRQOL has currently achieved 
widespread acceptance [9]. The objective of this study was to 
determine HRQOL in COPD patients and also to measure the differences 
in their quality of life according to gender, and severity of the disease. 
The Short Form Health Survey (SF-12) has been shown to be a valid 
evaluation tool with excellent measurement properties in patients with 
chronic respiratory conditions such as COPD and asthma. This health 
survey questionnaire allows calculating the physical health status 
and the mental health status of the patient when administered to all 
patients [10-13].
In most of the patients, lower PCS-12 physical health component 
summary scores than that of the MSC-12 mental health component 
summary scores in patients with COPD has been reported [14].
Another study shows that there is a moderate association between 
COPD severity and HRQOL using FEV1% value and also observed that 
within each stage of severity there is a large variation in deterioration; 
accordingly both clinical and HRQOL measures ought to be considered 
in the evaluation of the COPD patients [15]. The relationship between 
disease severity and HRQOL was made using FEV1%, HRQOL was 
predicted by staging the disease, based on the GOLD and British Thoracic 
Society guidelines [16]. In a COPD case finding a program in community 
pharmacists as another technique to decrease COPD under diagnosis, 
drug specialists could choose and evaluated patients utilizing a survey 
and spirometry testing [17]. Furthermore, a study demonstrates that 
even with the minor change in FEV1 values, patients felt much better, 
due to which their HRQOL enhanced to a greater extent [18].
Ozalevli and Ucan [19] observed that MRC based dyspnea score was 
compared with spirometry measurement FEV1 values and reported that 
dyspnea has a greater impact on HRQOL than spirometry or functional 
measurements in the COPD patients. The most commonly used scale 
to measure dyspnea is MRC scale, because of its simplicity, ease of 
administration and established validation as a useful marker in COPD, 
and the study concluded that MRCS as the most suitable scale used in 
COPD patients [20]. Hajiro et al. [21] showed that dyspnea is the main 
factor that separates disease-specific health-related quality of life and 
analyzed that it has a strong correlation with impairments in the HRQOL 
in COPD patients. According to Oga et al.’s [22] study showed that 
different significant characteristics are observed from different dyspnea 
measurements; it is important to follow dyspnea using appropriate 
measurements. Increase airflow limitation was not only compared 
with the progressive dyspnea, but also with other factors such as 
psychological status or worsening of diffusing capacity of the patient.
Males are prone to develop COPD, the high prevalence rate in males is 
due to a higher prevalence of smoking in this gender, and moreover, 
females are less exposed to smoking when compared to males [23]. 
Prigatano et al. [24] reported that quality of life was affected due to 
smoking regardless the presence of COPD. Younger COPD patients 
reported with worse quality of life and current smoker patient with high 
FEV1 values than ex-smoker patients with COPD and also concluded 
that COPD severity was influenced by smoking status, but current 
smoking affected the quality of life by causing COPD exacerbations 
although it did not have a direct impact on quality of life deterioration.
In Fletcher and Peto’s [25] study, COPD is described by a dynamic 
decrease in FEV1 with age. In light of this, more established age 
individuals anticipated that would have COPD. The review proposed 
that analysis and medicinal treatment ought to be given by considering 
both biomedical and psychosocial impacts.
CONCLUSION
This study shows that there were contrasts in COPD seriousness as per 
sexual orientation, with altogether higher rates of men contrasted with 
women. There is no critical physical well-being distinction among men 
and women, but the mental health is significantly higher in women when 
compared to men. HRQOL is impaired, and moreover, it progressively 
worsens with increasing severity of the disease. This study shows 
that patients with higher smoking index are having more likelihood of 
developing the COPD disease and dyspnea has a great impact on HRQOL 
of patients. Psychological assessment is important for improving COPD 
patients’ symptoms, HRQOL, and better treatment. In conclusion of this 
study, dyspnea greatly impacts the HRQOL of patients with COPD and 
evaluation of COPD patients should not be based only on pulmonary 
function tests, but rather additionally in view of estimation of patient’s 
HRQOL.
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Fig. 1: Mean scores of the physical component summary‑12 
and the mental component summary‑12 in chronic obstructive 
pulmonary disease patients according to gender
Fig. 2: Mean scores of the physical component summary and the 
mental component summary in chronic obstructive pulmonary 
disease patients according to the severity of the disease
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